Trial Search Results

Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study

The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Funded by Toyo Shinyaku Co Ltd

Stanford Investigator(s):


  • Drug: Pine Bark Extract (Flavangenol┬«)




Inclusion Criteria:

   - Systolic blood pressure between 125 and 159 mmHg and diastolic blood pressure (DBP) <
   100 mmHg

   - Body mass index (BMI) 25.0-34.9

   - Triglycerides (TG) < 450 mg/dL

   - Low Density Lipoprotein (LDL) < 200 mg/dL

   - Fasting blood glucose (FBG) < 126 mg/dL

Exclusion Criteria:

   - DBP > 95 mmHg

   - LDL > 170 mg/dL

   - TG > 300 mg/dL

   - FBG > 110 mg/dL

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Rebbeca Drieling